Lori Pierce

Professor / Vice Provost for Academic and Faculty Affairs at the University of Michigan at Harvard Medical School

Biography

Harvard Medical School

Dr. Pierce is a radiation oncologist, professor, and Vice Provost for Academic and Faculty Affairs at the University of Michigan. She is also director of the Michigan Radiation Oncology Quality Consortium. A national leader in breast cancer research, Dr. Pierce was previously a Senior Investigator at the National Cancer Institute, National Institutes of Health and in 1992, joined the faculty at the University of Michigan where she has focused her career primarily on the treatment of breast cancer.

An active ASCO member since 1992, Dr. Pierce is a past member of multiple ASCO committees including the Government Relations Committee, Annual Meeting Scientific Program Committee, and the Conquer Cancer Foundation Nominating Committee, and she served as a mentor for the Leadership Development Program from 2015 to 2018. She previously served on the ASCO Board of Directors from 2010 – 2014 and was named a Fellow of ASCO (FASCO) in 2015.

With over 180 manuscripts and book chapters published, Dr. Pierce has received numerous teaching and leadership awards including the American Association of Women Radiologists' Marie Curie Award and the Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award. In 2018, she was elected into the National Academy of Medicine. Most recently, Dr. Pierce was selected as the 2019 Woman of the Year by the United Way of Washtenaw County (UWWC) of Michigan.

Dr. Pierce completed her undergraduate degree in biomedical engineering at the University of Pennsylvania and her medical degree at Duke University. She completed her internship at the Thomas Jefferson University Hospital and her residency and chief residency in Radiation Oncology at the University of Pennsylvania.

Areas of Interest

  • Breast-conserving therapy for breast cancer
  • The effect of radiation in patients with BRCA-1 or BRCA-2 mutations
  • The use of intensity modulated radiotherapy in the treatment of breast cancer
  • Indications for post-mastectomy radiotherapy
  • The use of radiosensitizers in patients with refractory disease

Clinical Interests

  • Breast cancer

Honors & Awards

  • 2019-23 ASCO President-elect, President, Chair of the Board, Past-President
  • 2019 Woman of the Year Award, United Way of Washtenaw County
  • 2018 National Academy of Medicine member
  • 2018 Zeta Phi Beta Sorority, Inc., Platinum & Pearls Gala, Community Award
  • 2018 Hologic Inc, Endowed Women Who Conquer Cancer Mentorship
  • 2017 MICHR Distinguished Clinical and Translational Research Mentor Award
  • 2017-19 Castle Connolly’s Exceptional Women in Medicine
  • 2017 Robert E. Guenzel Award, United Way of Washtenaw County
  • 2013-19 Castle Connolly’s America’s Top Physicians for Cancer
  • 2015 Malcolm Bagshaw Visiting Professor, Stanford University
  • 2015 Fellow Inductee, American Society for Clinical Oncology (ASCO)
  • 2013-17 Listed among Castle Connolly’s “America’s Top Physicians for Cancer”
  • 2013 AAWR Marie Curie Award
  • 2013 League of Educational Excellence Award
  • 2010-18 Susan G. Komen for the Cure Scholar
  • 2010-19 Member of Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Steering Committee
  • 2010 Sara Goddard Power Award from the American Women’s Caucus
  • 2010 Fellow Inductee, American Society for Radiation Oncology (ASTRO)
  • 2007 AMA Women Physician Mentor Award
  • 2002 Lifetime Achievement Award, Sister’s Network, Inc.
  • 1999 Included in Good Housekeeping’s “Best Doctors for Breast, Lung and Colorectal Cancer”
  • 1998-17 Listed among Castle Connolly’s “America’s Top Doctors for Breast Cancer”
  • 1995 ESTRO Travel Award
  • 1995-98 American Cancer Society Clinical Oncology Career Development Award

Credentials

  • MD, Duke University, 1985
  • Residency, University of Pennsylvania, Radiation Oncology, 1986-89
  • Chief Resident, University of Pennsylvania, 1988-89
  • Board Certification: Radiation Oncology

Grants

  • (PI: Pierce), 10/1/15– 9/30/19, Breast Cancer Research Foundation: Breast Cancer Cell Sensitivity to Radiotherapy in the Presence of Targeted Therapies and Predictors of Early vs. Late Response, Role: Principal Investigator.
  • (PI:Pierce), 2/1/11 – 1/31/20, Michigan Blue Cross Blue Shield: The Michigan Radiation Oncology Quality Consortium, Role: Principal Investigator, Director.

Published Articles or Reviews

Selected from 164 publications

  • Pierce L, Phillips K, Griffith K, Buys S, Gaffney D, Moran M, Haffty B, Ben-David M, Kaufman B, Merajver S, Balmaña J, Kierovitz A, Domchek S. Local therapy in BRCA1 and BRCA 2 mutation carriers with operable breast cancer: Comparison of breast conservation and mastectomy. Br Can Res Treat. 121(2):389-398, 2010. PMC2936479.
  • Speers C, Zhao S, Liu M, Bartelink H, Pierce LJ, Feng F. Development and validation of a novel radiosensitivity signature in human breast cancer. Clin Can Res. 21(16):3667-77, 2015. doi:10.1158/1078-0432.CCR-14-2898. PMID:25904749
  • Jagsi R, Griffith K, Hayman J, Boike T, Walker E, Nurushev T, Grills I, Moran J, Feng M, Hayman J, Pierce LJ. Differences in the acute toxic effects of breast radiotherapy by fractionation schedule: Comparative analysis of physician-assesses and patient-reported outcomes in a large multicenter cohort. JAMA Oncol. 1(7):918-930, 2015. PMID:26247417
  • Pierce L, Feng M, Griffith K, Jagsi R, Boike T, Dryden D, Gustafson G, Benedetti L, Matuszak M, Nurushev T, Haywood J, Radawski J, Speers C, Walker E, Hayman J, Moran J on behalf of MROQC, the Michigan Radiation Oncology Quality Consortium. Recent time trends and predictors of heart dose from breast radiotherapy in a large quality consortium of radiation oncology practices. Int J Rad Onc Biol Phys, 99(5);1154-1161,2017. Jul 22. pii: S0360-3016(17)33606-4. doi: 10.1016/j.ijrobp.2017.07.022. PMID: 28927756.
  • Jagsi R, Griffith K, Bellon J, Woodward W, Horton J, Ho A, Feng F, Speers C, Hayes D, Overmoyer B, Sabel M, Schott A, Pierce L. Concurrent veliparib with chest-wall and nodal radiotherapy in patients with inflammatory or locoregionally recurrent breast cancer: The TBCRC 024 Phase 1 Multicenter Study. J Clin Oncol, 2018. doi: 10.1200/JCO.2017.77.2665. PMID:29558281.
  • Jagsi R, Griffith K, Moran J, Ficaro E. March R, Dess R, Chung E, Liss A, Hayman J, Mayo C, Flaherty K, Corbett J, Pierce L. A randomized comparison of radiation therapy techniques in the management of node-positive breast cancer: Primary outcomes analysis. Int J Rad Onc Biol Phys: 101(5); 1149-1158, 2018. PMID:30012527

Videos

Read about executive education

Other experts

Looking for an expert?

Contact us and we'll find the best option for you.

Something went wrong. We're trying to fix this error.